Know Cancer

forgot password

A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer

Phase 2
18 Years
Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer

Tetrathiomolybdate or TM, a drug developed for Wilson's Disease, removes copper from the
bloodstream. Copper is a key factor in angiogenesis (blood vessel growth)- a process that
occurs normally in the body but becomes uncontrolled in cancerous cells. Tetrathiomolybdate
essentially wages war against copper, which serves to choke off tumor growth. Realizing the
key role of copper in angiogenesis, researchers have begun exploring treatment with
Tetrathiomolybdate for different types of cancers. This clinical trial will evaluate the
effectiveness of Tetrathiomolybdate in the treatment of patients with hormone refractory
prostate cancer. Hormone refractory prostate cancer refers to advanced disease in which the
patient no longer responding to conventional hormonal treatment.

Inclusion Criteria

Patients must have histologic diagnosis of adenocarcinoma of the prostate with progression
following hormonal therapy and antiandrogen withdrawal.

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the time to progression and pattern of progression of prostate cancer in patients with androgen-independent prostate cancer treated with tetrathiomolybdate.

Principal Investigator

David C. Smith, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

The University of Michigan Comprehensive Cancer Center


United States: Food and Drug Administration

Study ID:

UMCC 9962



Start Date:

May 2001

Completion Date:

Related Keywords:

  • Prostate Cancer
  • Prostatic Neoplasms



The University of Michigan Comprehensive Cancer CenterAnn Arbor, Michigan  48109